Mechanistically, PRMT5 is recruited to the promoter region of KCNMB4, where it facilitates H3R2me2s and enhances gene expression of KCNMB4. Inhibition of PRMT5 significantly sensitized NPC cells to paclitaxel, both in vitro and in vivo. The gene discussed is PRMT5; the disease is nasopharyngeal carcinoma.